GoodRx Holdings (GDRX) Net Income towards Common Stockholders (2019 - 2026)

GoodRx Holdings has disclosed Net Income towards Common Stockholders across 8 years of filings, most recently posting $8.5 million for Q2 2026.

• In Q2 2026, Net Income towards Common Stockholders fell 33.54% year-over-year to $8.5 million; the TTM figure through Jun 2026 stood at $16.2 million (down 53.04% YoY), while the FY2025 annual figure was $30.4 million, up 85.72% from the prior year.
• Net Income towards Common Stockholders came in at $8.5 million for Q2 2026 at GoodRx Holdings, up from $1.2 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of $58.8 million in Q2 2023 to a low of -$41.7 million in Q3 2022.
• Average Net Income towards Common Stockholders over 5 years is $824333.3, with a median of $2.6 million recorded in 2024.
• The largest YoY upside for Net Income towards Common Stockholders was 4254.49% in 2023 against a maximum downside of 1211.82% in 2023.
• Over 5 years, Net Income towards Common Stockholders stood at -$2.0 million in 2022, then plunged by 1211.82% to -$25.9 million in 2023, then soared by 126.05% to $6.7 million in 2024, then declined by 19.51% to $5.4 million in 2025, then surged by 57.35% to $8.5 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $8.5 million in Q2 2026, $1.2 million in Q1 2026, and $5.4 million in Q4 2025.